CoChat

IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia

Open access
Schuster, Steven R., Rajkumar, Sundararajan Vincent, Dispenzieri, Angela, Morice, William, Aspitia, Alvaro Moreno, Ansell, Stephen, Kyle, Robert, Mikhael, Joseph · 2010 · American Journal of Hematology
Cited by 111

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

IgM multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) are two distinct hematologic entities with the common finding of an IgM monoclonal gammopathy. Distinguishing these two diagnoses is critical as the approach to therapy is different. A priori, we defined IgM MM as a symptomatic clonal plasma cell proliferative disorder characterized by an IgM monoclonal protein (regardless of size), 10% or more plasma cells on bone marrow biopsy, plus the presence of lytic bone lesions and/or translocation t(11;14). Twenty‐one patients met this definition of IgM MM. All 21 patients had lytic bone lesions. Of the 16 evaluated with FISH, 6 (38%) demonstrated t(11;14). Median overall survival was 30 months, which is similar to non‐IgM myeloma patients treated during this period and shorter than what would be expected for WM. In this, the largest series of patients with IgM MM, we describe the clinical features and prognosis of patient with IgM MM using a strict definition for the disease. The subset of patients without lytic lesions or t(11;14) but with immunophenotypic features suggestive of MM need further study. Am. J. Hematol., 2010. © 2010 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ajh.21845

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Review of 1027 Patients With Newly Diagnosed Multiple Myeloma

    Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447 · cited 1×

    “In this article, the largest known series of patients with IgM MM, we show that patients defined as IgM MM have a median overall survival of 30 months, similar to non-IgM myeloma patients treated during this period and shorter than what would be expected for WM [6].”
    ResultSelf-citation
  • Prevalence of monoclonal gammopathy of undetermined significance

    Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423 · cited 3×

    “Before progression to MM, one patient met criteria for IgM MGUS, and a second patient met criteria for Smoldering IgM MM [10,11].”
    BackgroundMethodSelf-citation
  • Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

    Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921

    Self-citation

Cited by

See all 111

Metadata

Authors
Schuster, S. R., Rajkumar, S. V., Dispenzieri, A., Morice, W., Aspitia, A. M., Ansell, S., Kyle, R., & Mikhael, J.
Venue
American Journal of Hematology
Publisher
Wiley
Published
2010-10-25
Volume
85
Issue
11
Pages
853-855
ISSN
  • 0361-8609 (ISSN-L)
  • 1096-8652
OpenAlex
W1994753912
Cited by
111
References
3
FWCI
5.93
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.